| Price | 11.00p on 31-12-2025 at 19:40:04 |
|---|---|
| Change | -0.30p -2.65% |
| Buy | 11.50p |
| Sell | 10.50p |
| Last Trade: | Buy 30,000.00 at 11.20p |
| Day's Volume: | 39,783 |
| Last Close: | 11.00p |
| Open: | 11.50p |
| ISIN: | GB00B02LCQ05 |
| Day's Range | 11.00p - 11.70p |
| 52wk Range: | 5.25p - 11.90p |
| Market Capitalisation: | £675.56m |
| VWAP: | 11.28271p |
| Shares in Issue: | 6.14b |
Sector: Medicine and Biotech
Listed In: FTSE AIM All-Share,
Allergy Thera. (AGY) Latest Trades |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Buy* | 30,000 | 11.20p | Ordinary |
11:39:15 - 31-Dec-25 |
| Buy* | 786 | 11.19p | Ordinary |
09:09:13 - 31-Dec-25 |
| Buy* | 3,000 | 11.50p | Suspected BUY Trade |
09:00:16 - 31-Dec-25 |
| Buy* | 150 | 11.19p | Ordinary |
12:58:02 - 30-Dec-25 |
| Buy* | 1,734 | 11.239p | Ordinary |
12:25:58 - 30-Dec-25 |
| Buy* | 1,000 | 11.50p | Ordinary |
09:50:08 - 30-Dec-25 |
| Buy* | 3,000 | 11.60p | Suspected BUY Trade |
09:00:22 - 30-Dec-25 |
| Sell* | 20,000 | 10.888p | Ordinary |
08:52:13 - 30-Dec-25 |
| Buy* | 13,000 | 11.30p | Suspected BUY Trade |
16:35:00 - 29-Dec-25 |
| Sell* | 50,000 | 11.066p | Ordinary |
14:08:48 - 29-Dec-25 |
Allergy Thera. (AGY) Regulatory News |
||
| Date | Source | Headline |
|---|---|---|
| 29th Dec 2025 1:07 pm | RNS | Results of General Meeting |
| 29th Dec 2025 1:07 pm | RNS | Results of General Meeting |
| 16th Dec 2025 7:00 am | RNS | Grassmuno® marketing authorisation in Germany |
| 12th Dec 2025 7:00 am | RNS | Authority for allotment of New Shares |
| 11th Dec 2025 7:00 am | RNS | Prelim Results and publication of Annual Report |
| 9th Dec 2025 7:00 am | RNS | Primary Safety Endpoint Met in PROTECT trial |
| 6th Nov 2025 7:22 am | RNS | Company to Evaluate Dual Listing on HKEX |
| 30th Oct 2025 7:00 am | RNS | G308 Phase III Year 2 Patient Screening Starts |
| 29th Oct 2025 7:00 am | RNS | Warrant Exercise and Paydown of Debt |
| 16th Oct 2025 7:00 am | RNS | Further progress in Phase I/IIa PROTECT trial |